HIGHLIGHTS
- who: Claudio Tana and colleagues from the Department of Medicine and Surgery, University-Hospital of Parma, Parma, Italy have published the Article: Molecular Sciences, in the Journal: (JOURNAL)
- what: Following these results, the ACCP guidelines do not recommend ASA/antiplatelet drugs in VTE prevention in hospitalized patients, suggesting further studies aimed at investigating the VTE risk reduction with antiplatelet drugs .
- how: Similar results were obtained with edoxaban versus warfarin in fragile patients confirming the favorable risk/benefit ratio of NOACs in this population versus standard therapy. While this feature can be useful to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.